Adapter-based retroviral vector system for the selective transduction of target cells

US12365916B2 · kind B2 · utility

Assignee

• MILTENYI BIOTEC B.V. & CO. KG · DE

Inventors

• Thomas Schaser · Rösrath, DE
• Nicole Cordes · Cologne, DE
• Joerg Mittelstaet · Cologne, DE
• Andrew Kaiser · Moitzfeld, DE

Key dates

• Filing date: Oct 26, 2018
• Grant date: Jul 22, 2025
• Expiry date: Nov 27, 2040

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2810/859
• WIPO field: Biotechnology
• WIPO sector: Chemistry

Abstract

The present invention provides a composition comprising i) a pseudotyped retroviral vector particle or virus-like particle thereof comprising a) one envelope protein with antigen-binding activity, wherein said envelope protein is a recombinant protein that does not interact with at least one of its native receptor(s) and is fused at its ectodomain to a polypeptide comprising an antigen binding domain specific for a tag of a tagged polypeptide, and wherein said envelope protein is protein G, HN or H derived from the Paramyxoviridae family, and b) one envelope protein with fusion activity derived from the Paramyxoviridae family, and ii) said tagged polypeptide, wherein said tagged polypeptide binds specifically to an antigen expressed on the surface of a target cell, thereby transducing the target cell with said retroviral vector particle or thereby inducing uptake of the virus-like particle into the target cell. A pharmaceutical composition thereof and an in vitro method for transduction of targets cells with said vector particle are also disclosed.